Skip to main content
main-content

SGLT2 inhibitors


Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.


Highlights

01-13-2022 | SGLT2 inhibitors | News

Residual cardiorenal risk high after SGLT2 inhibitor initiation in diabetic CKD

People with type 2 diabetes and chronic kidney disease have a high residual risk for cardiorenal events and high rates of treatment failure after initiation of SGLT2 inhibitors, real-world study findings indicate.

11-01-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

10-28-2021 | Dapagliflozin | News

PRESERVED-HF: Dapagliflozin improves health status in people with HFpEF

Treatment with the SGLT2 inhibitor dapagliflozin improves symptoms and physical function in people with heart failure and preserved ejection fraction, suggest findings from the PRESERVED-HF trial.

More on SGLT2 inhibitors

SGLT2 inhibitors and finerenone for kidney disease treatment

Ian de Boer joins Amrit Lamba to discuss how these medications will influence the treatment of kidney disease in people with DKD.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.
Image Credits